Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.
Advancements in next-generation sequencing technologies, increasing adoption of precision oncology, and rising cancer incidence worldwide are driving the genomics in cancer care market growth.Austin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback